Home World News Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In... World News Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 714 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Hopes for the future of cancer research – a video from... April 16, 2023 Five Questions With…Keon. June 16, 2022 The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment... September 19, 2020 How Financial Toxicity Can Impact Cancer Caregivers and Where to Find... August 23, 2022 Load more HOT NEWS FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated... Avasopasem Shields Normal Cells from Radiation, Helps Kill Cancer Cells Cancer and the Holidays
